Giovanni Martinelli

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. pmc Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma
    Pf Ferrucci
    Hematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20100 Milan, Italy
    Ecancermedicalscience 2:79. 2008
  2. ncbi request reprint Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma
    Giovanni Martinelli
    European Institute of Oncology, Milan, Italy
    Br J Haematol 123:271-7. 2003
  3. ncbi request reprint ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis
    G Martinelli
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Br J Haematol 125:584-9. 2004
  4. doi request reprint Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group
    G Martinelli
    Division of Haematology, European Institute of Oncology, Milan, Italy
    Ann Oncol 20:1993-9. 2009
  5. ncbi request reprint Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients
    G Martinelli
    Division of Hematoncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Leuk Lymphoma 44:1919-23. 2003
  6. doi request reprint Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]
    Giovanni Martinelli
    Division of Haematoncology, European Institute of Oncology, Milan, Italy
    Leuk Lymphoma 50:925-31. 2009
  7. ncbi request reprint Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified "TANDEM" transplant program
    G Martinelli
    Department of Hematology Oncology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy
    Leuk Lymphoma 44:299-302. 2003
  8. doi request reprint Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma
    Anna Vanazzi
    Hematoncology Division, European Institute of Oncology, Milan, Italy
    Hematol Oncol 32:10-5. 2014
  9. ncbi request reprint Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat
    Daniele Laszlo
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Eur J Haematol 72:264-7. 2004
  10. ncbi request reprint Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity
    Maurizio Civelli
    Cardiology Unit, European Institute of Oncology, University of Milan, Italy
    Int J Cardiol 111:120-6. 2006

Detail Information

Publications95

  1. pmc Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma
    Pf Ferrucci
    Hematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20100 Milan, Italy
    Ecancermedicalscience 2:79. 2008
    ....
  2. ncbi request reprint Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma
    Giovanni Martinelli
    European Institute of Oncology, Milan, Italy
    Br J Haematol 123:271-7. 2003
    ..Based on our preliminary data, the combination of chlorambucil with rituximab seemed to be well tolerated and active. Its definitive role in the treatment of low-grade NHL should be further evaluated in randomized trials...
  3. ncbi request reprint ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis
    G Martinelli
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Br J Haematol 125:584-9. 2004
    ..Long-term results of the ongoing randomized trial, comparing ABVD versus high-dose intensity weekly regimens will be useful to confirm our results...
  4. doi request reprint Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group
    G Martinelli
    Division of Haematology, European Institute of Oncology, Milan, Italy
    Ann Oncol 20:1993-9. 2009
    ..Primary breast lymphoma (PBL) of low-grade histology is a rare disease. This multicentric retrospective study was carried out to determine clinical features, prognosis and relapse...
  5. ncbi request reprint Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients
    G Martinelli
    Division of Hematoncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Leuk Lymphoma 44:1919-23. 2003
    ..Such combination could be considered as first line treatment for early stage HD patients with favorable prognosis and/or not suitable for anthracyclines-containing regimens...
  6. doi request reprint Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]
    Giovanni Martinelli
    Division of Haematoncology, European Institute of Oncology, Milan, Italy
    Leuk Lymphoma 50:925-31. 2009
    ..Our results confirm that CT could be considered as first line therapy for newly diagnosed gastric DLBC lymphoma; IF RT delivered in those patients achieving CR after induction CT is able to prevent local relapse...
  7. ncbi request reprint Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified "TANDEM" transplant program
    G Martinelli
    Department of Hematology Oncology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy
    Leuk Lymphoma 44:299-302. 2003
    ..This approach could reduce the toxic effects and maintain the efficacy of therapy at the same time...
  8. doi request reprint Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma
    Anna Vanazzi
    Hematoncology Division, European Institute of Oncology, Milan, Italy
    Hematol Oncol 32:10-5. 2014
    ..These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients...
  9. ncbi request reprint Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat
    Daniele Laszlo
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Eur J Haematol 72:264-7. 2004
    ....
  10. ncbi request reprint Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity
    Maurizio Civelli
    Cardiology Unit, European Institute of Oncology, University of Milan, Italy
    Int J Cardiol 111:120-6. 2006
    ....
  11. doi request reprint Rituximab in lymphocyte-predominant Hodgkin disease
    Hatem A Azim
    Division of Haematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Oncology 76:26-9. 2009
    ..Lymphocyte-predominant Hodgkin disease (LPHD) differs in biology and clinical behaviour from classic Hodgkin disease. Almost 100% of LPHD neoplastic cells express CD20 and thus rituximab could be effective; yet limited data are available...
  12. doi request reprint Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients
    Paola Bertazzoni
    Hematoncology Division, European Institute of Oncology, Milan, Italy
    Leuk Lymphoma 51:1485-93. 2010
    ..The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5% of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL...
  13. ncbi request reprint Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
    Daniela Cardinale
    Cardiology Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Circulation 114:2474-81. 2006
    ..Angiotensin-converting enzyme inhibitors slow the progression of left ventricular dysfunction in different clinical settings, but their role in the prevention of cardiotoxicity has never been investigated...
  14. ncbi request reprint High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas
    Pier F Ferrucci
    Melanoma and Sarcoma Division, European Institute of Oncology, Milan, Italy
    Br J Haematol 139:590-9. 2007
    ..Maximum tolerated dose was not clearly defined according to dosimetry and clinical toxicities, and further studies are needed to confirm the toxicity profile and evaluate efficacy...
  15. doi request reprint Who should be really considered as a poor mobilizer in the plerixafor era?
    Giovanna Andreola
    Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
    Transfus Apher Sci 47:27-32. 2012
    ..0×10(6) CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients...
  16. ncbi request reprint The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Pathol 206:337-45. 2005
    ..Our data suggest that TA-p63 is overexpressed in high-grade FL, possibly independent of the occurrence of gene abnormalities, and that it may be involved in the highly complex mechanism of regulation of apoptosis of FL cells...
  17. ncbi request reprint Circulating endothelial cells as a novel marker of angiogenesis
    Patrizia Mancuso
    Division of Hematology Oncology, European Institute of Oncology, and IFOM FIRC Institute of Molecular Oncology, Milan, Italy
    Adv Exp Med Biol 522:83-97. 2003
    ..Furthermore, this assay offers insight into anti-angiogenic activity of different drugs...
  18. ncbi request reprint Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy
    Giovanni Martinelli
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1979-83. 2005
    ....
  19. doi request reprint Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation
    Giovanna Andreola
    Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
    Eur J Haematol 88:154-8. 2012
    ..0 × 10(6) /kg in a median number of procedures of one. Although preliminary, these data show the combination of biosimilar filgrastim and plerixafor is effective and provides a non-toxic approach to mobilise stem cells...
  20. ncbi request reprint Stroma cells: a novel target of herceptin activity
    Chiara Corsini
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Clin Cancer Res 9:1820-5. 2003
    ..We investigated the activity of herceptin (HER), a humanized monoclonal antibody widely used for the treatment of HER2-overexpressing epithelial cancer, toward stroma cell lines L87/4 and L88/5...
  21. doi request reprint Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study
    Daniele Laszlo
    Department of Hematology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 28:2233-8. 2010
    ....
  22. ncbi request reprint Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors
    Manuela Capillo
    Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Clin Cancer Res 9:377-82. 2003
    ....
  23. ncbi request reprint Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells
    Cristina Rabascio
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Cancer Res 64:4373-7. 2004
    ..Taken together, our data indicate that the quantitative evaluation of circulating VE-C RNA is a specific and highly promising tool with which to investigate the angiogenic phenotype of cancer patients...
  24. ncbi request reprint Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer
    Pier Francesco Ferrucci
    Divisions of Hemato oncology and Biostatistics and Epidemiology, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6039-46. 2004
    ..The population on which the study was conducted was drawn from stage III breast cancer patients undergoing high-dose chemotherapy and autologous transplantation with PBPCCs...
  25. ncbi request reprint N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?
    Maria T Sandri
    Epidemiology and Biostatistics Division, Hematoncology Division, European Institute of Oncology, Milan, Italy
    Clin Chem 51:1405-10. 2005
    ..Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC)...
  26. doi request reprint Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
    Simona Soverini
    Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Leuk Res 35:1527-9. 2011
    ..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse...
  27. doi request reprint The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution
    Demetrio Aricò
    Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy
    Cancer Biother Radiopharm 24:271-5. 2009
    ..Following these dosimetric results, both patients did not receive the planned therapy. These findings support the recommendation to include dosimetry in high-dose RIT...
  28. doi request reprint Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
    Giovanni Martinelli
    Istituto Europeo di Oncologia, Divisione di Ematologia, Milan, Italy
    J Clin Oncol 28:4480-4. 2010
    ....
  29. ncbi request reprint Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia
    Ilaria Iacobucci
    Institute of Hematology L e A Seràgnoli Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, Via Massarenti, 9 40138 Bologna, Italy
    Curr Cancer Drug Targets 13:791-810. 2013
    ..In this review, we reported recent advances obtained in the knowledge of the genomic complexity of chronic myeloid leukemia and acute leukemias thanks to the use of high-throughput technologies, such as SNP array. ..
  30. ncbi request reprint Fludarabine combination regimen severely affected peripheral blood stem cell mobilization
    Daniele Laszlo
    Department of Hematoncology, European Institute of Oncology, Milan, Italy
    Acta Haematol 111:228-9. 2004
  31. ncbi request reprint Procalcitonin as a useful marker of infection in hemato-oncological patients with fever
    Maria T Sandri
    Laboratory Medicine Unit, European Institute of Oncology, Milan, Italy
    Anticancer Res 28:3061-5. 2008
    ..The diagnostic utility of procalcitonin (PCT) and C-reactive protein (CRP) to discriminate between infective fever and fever due to inflammation was assessed in hemato-oncological patients treated with aggressive chemotherapy...
  32. doi request reprint Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
    Francesco Lanza
    Section of Hematology and BMT Unit, Cremona Hospital, Cremona, Italy Department of Hematology and Oncological Sciences, Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy Section of Hematology, University Hospital of Ancona, Ospedali Riuniti, Ancona, Italy Hemato Oncology Unit, Istituto Europeo Oncologico, Milan, Italy Section of Hematology, Reggio Calabria Hospital, Reggio Calabria, Italy Section of Hematology, University Hospital of Bari, Bari, Italy Section of Hematology, Tricase Hospital, Tricase, Italy Section the of Hematology, Rimini Hospital, Rimini, Italy Section of Hematology, University Hospital Ferrarotto, Policlinico Vittorio Emanuele, Catania, Italy Section of Hematology, Humanitas Hospital BMT Unit, S Raffaele Hospital, Milan, Italy Section of Hematology, Hospital Casa Sollievo Sofferenza, Japan
    Transfusion 54:331-9. 2014
    ..We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients...
  33. doi request reprint Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease
    Rocco Pastano
    Hematoncology Division, Bone Marrow Transplant Unit, European Institute of Oncology, Milan, Italy
    Int Immunol 24:583-91. 2012
    ....
  34. ncbi request reprint Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Int J Cancer 112:71-7. 2004
    ..Our data suggest that the t(6;14) translocation may be extremely uncommon in FL and that a deregulated expression of cyclin D3, possibly due to epigenetic mechanisms, may be involved in the pathogenesis of high-grade tumors...
  35. ncbi request reprint In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue
    Chiara Dell'agnola
    Division of Hematology Oncology, Experimental Oncology IFOM FIRC Institute of Molecular Oncology, Pathology Laboratory Medicine, and Head and Neck Surgery, European Institute of Oncology, Milan, Italy
    Exp Hematol 30:905-14. 2002
    ..We studied the in vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue collected from adults with head and neck cancer...
  36. ncbi request reprint R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma
    Juan Montoro
    Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Electronic address
    Transfus Apher Sci 50:411-4. 2014
    ..Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events. ..
  37. ncbi request reprint Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
    Daniela Cardinale
    Cardiology Unit, Istituto Europeo di Oncologia, University of Milan, Via Ripamonti 435, 20141 Milan, Italy
    Circulation 109:2749-54. 2004
    ..The time course of the subclinical myocardial damage and its impact on the clinical outcome have never been investigated previously...
  38. ncbi request reprint Chemotherapy during pregnancy: what is really safe?
    Fedro Peccatori
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Lancet Oncol 5:398. 2004
  39. ncbi request reprint ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication
    Hatem A Azim
    the Departments of Medicine, Division of Haematology Oncology, European Institute of Oncology, Milan, Italy Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt and Pathology, European Institute of Oncology, Milan, Italy
    J Egypt Natl Canc Inst 19:176-7. 2007
    ..It remains unclear whether ERCC1 could serve as a predictive marker for cisplatin in this disease requiring further studies. Key Words : ERCC1 -Large B-cell lymphoma -Cisplatin resistance...
  40. ncbi request reprint CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma
    Francesco Bertolini
    Divisions of Hematology Oncology, Experimental Oncology IFOM Institute of Molecular Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Res 62:3106-12. 2002
    ..Taken together, these data support clinical studies on CXCR4 neutralization in NHL patients by monoclonal antibodies or CXCR4 antagonists...
  41. ncbi request reprint Intrathecal chemotherapy in carcinomatous meningitis from breast cancer
    Laura Orlando
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 22:3057-9. 2002
    ..We therefore evaluated the efficacy of an ITC regimen for patients presenting with carcinomatous meningitis from breast cancer...
  42. ncbi request reprint High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment
    Marta Cremonesi
    Division of Medical Physics, European Institute of Oncology, Milan, Italy
    J Nucl Med 48:1871-9. 2007
    ..The second goal was to verify the safety of the prescribed activity and the best timing of stem cell reinfusion...
  43. doi request reprint Extramedullary myeloid sarcoma of the breast
    Hatem A Azim
    Department of Medicine, Division of Haematology Oncology, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4041-3. 2008
  44. doi request reprint Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta
    Roberto Cairoli
    Division of Haematology, Niguarda Hospital, Milan, Italy Division of Haematology, Department of Internal Medicine, Valduce Hospital, Como, Italy
    Am J Hematol 88:594-600. 2013
    ..017), with 1.1% increase of hazard for each 1.0 × 10(9) /L WBC increment. KIT mutations lacked prognostic value for survival and showed only a trend for relapse incidence (P = 0.069)...
  45. doi request reprint Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report
    Federica Gigli
    European Institute of Oncology, Hematoncology Divisione, Milan, Italy Humanitas Cancer Center, Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy Electronic address
    Transfus Apher Sci 49:205-7. 2013
    ..This experience may support the possibility to use only an immunomodulant treatment like ECP for the cGVHD, reducing the risk of complications of prolonged immunosuppressant treatment...
  46. doi request reprint Sexuality in patients undergoing haematopoietic stem cell transplantation
    Sarah Jayne Liptrott
    Division of Hemato Oncology, European Institute of Oncology, Milan, Italy
    Int J Hematol 94:519-24. 2011
    ....
  47. doi request reprint Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
    Nicoletta Testoni
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna and S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 114:4939-43. 2009
    ..I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  48. doi request reprint Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Ilaria Iacobucci
    Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 112:3847-55. 2008
    ..These results establish a previously unknown link between specific molecular defects that involve alternative splicing of the IKZF1 gene and the resistance to TKIs in Ph+ ALL patients...
  49. doi request reprint Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies
    Lorenzo Preda
    Division of Radiology, European Institute of Oncology IRCCS, Milan, Italy
    Eur Radiol 21:63-9. 2011
    ..To assess the safety of the non-ionic iso-osmolar contrast agent iodixanol on renal function in patients with monoclonal gammopathies undergoing CT...
  50. ncbi request reprint Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
    Annarita Conconi
    Division of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, AOU Maggiore della Carita, Novara, Italy Haematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy
    Br J Haematol 166:69-76. 2014
    ..Lower doses of the drug and, perhaps, different strategies including combination with additional agents need to be explored. ..
  51. pmc Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study)
    Marta Bruno Ventre
    Unit of Lymphoid Malignancies, Department of Onco Hematology, San Raffaele Scientific Institute, Milan, Italy Department of Radiation Oncology, Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Canada Auckland Hospital, Auckland, New Zealand Christie Hospital, Manchester, United Kingdom Seoul National University Hospital, Seoul, Korea Korea Cancer Center Hospital, Seoul, Korea Division of Hematology, European Institute of Oncology, Milan, Italy, Wesley Research Institute, Brisbane, Australia Northern Centre for Cancer, New Castle, United Kingdom Royal Prince Alfred Hospital, Sydney, Australia Oncology Institute of Southern Switzerland, Bellinzona, Switzerland Premion and Bond University, Tugun, Australia
    Oncologist 19:291-8. 2014
    ..The clinical features, management, and prognosis of stage I-II diffuse large B-cell lymphoma of the bone (PB-DLBCL) included in an international database of 499 lymphoma patients with skeletal involvement were reviewed...
  52. pmc Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation
    Enrica Morra
    Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Haematologica 94:102-12. 2009
    ..We describe the results of a systematic literature review and an explicit approach to consensus techniques, which resulted in recommendations for the management of primary non-APL acute myeloid leukemia...
  53. ncbi request reprint Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy
    Maria Teresa Sandri
    Division of Pathology, Laboratory Medicine Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Clin Chem 49:248-52. 2003
    ..We investigated whether cTnI measured by the Stratus CS (Dade Behring) would allow detection of minimal cTnI increases in patients treated with HDCT...
  54. ncbi request reprint Local thrombolytic therapy in cancer patients with central venous catheter occlusion in urgent need of antiblastic treatment: a single institution experience
    Alberto Agazzi
    Hematoncology Division, European Institute of Oncology, Milan, Italy
    J Thromb Thrombolysis 15:109-11. 2003
  55. doi request reprint Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    Gianantonio Rosti
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
    Blood 114:4933-8. 2009
    ..Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052...
  56. doi request reprint Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis
    Giancarlo Pruneri
    Leuk Res 32:1628-32. 2008
  57. doi request reprint A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial
    Serge Leyvraz
    Centre Pluridisciplinaire d Oncologie, University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland
    J Natl Cancer Inst 100:533-41. 2008
    ..A randomized trial was performed to test the impact of such dose intensification on the long-term survival of patients with small cell lung cancer (SCLC)...
  58. doi request reprint Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
    Daniela Cilloni
    Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano, Turin, Italy
    Haematologica 93:921-4. 2008
    ..WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified...
  59. doi request reprint Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia
    Michela Palmisano
    Institute of Hematology and Medical Oncology L e A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Hematology 13:1-12. 2008
    ....
  60. ncbi request reprint Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    Blood 102:1588-94. 2003
    ..055). We concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autologous transplantation...
  61. doi request reprint Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
    ..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial...
  62. ncbi request reprint Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 92:1721-2. 2007
    ..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild...
  63. ncbi request reprint Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
    Andrea Rinaldi
    Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Br J Haematol 132:303-16. 2006
    ..A combination of genomic and expression profiling suggested Syk inhibition as a new therapeutic strategy to be explored in lymphomas...
  64. ncbi request reprint Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Domenico Russo
    Unit of Blood Diseases and Cell Therapy, Brescia University, Brescia, Italy
    Br J Haematol 131:172-9. 2005
    ..Our prospective randomised study confirmed the anti-leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients...
  65. ncbi request reprint ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
    ....
  66. ncbi request reprint The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients
    Pier Paolo Piccaluga
    Haematologica 89:1269-71. 2004
    ..000). Moreover, the 6 patients with a bcr-abl/GAPDHx100,000 ratio <2 after 4 weeks of treatment had significantly better RFS (10.5 vs 4 months) (p=0.004)...
  67. ncbi request reprint No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
    Giuseppe Visani
    Department of Hematology, H San Salvatore, Pesaro, Italy
    Leuk Lymphoma 45:1361-4. 2004
    ....
  68. ncbi request reprint First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Res 28:987-90. 2004
    ..Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients...
  69. ncbi request reprint Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Chem 50:1205-13. 2004
    ..Point mutations within the ABL kinase domain are emerging as the most frequent mechanism for reactivation of kinase activity within the leukemic clone...
  70. ncbi request reprint Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia
    Pier Paolo Piccaluga
    Eur J Haematol 72:302-3. 2004
  71. ncbi request reprint Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
    Michele Ghielmini
    Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland
    Blood 103:4416-23. 2004
    ..In patients with FL, the administration of 4 additional doses of rituximab at 8-week intervals significantly improves the EFS...
  72. ncbi request reprint Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR37. 2003
  73. ncbi request reprint Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 88:1221-8. 2003
    ..Other genes that have been implicated at the rearrangement breakpoint are GR6 and RPN1 (both on 3q21). The aim of this study was to investigate the expression of the EVI1 fusion genes in AML patients with 3q21q26 syndrome...
  74. ncbi request reprint Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
    Paolo Corradini
    Hematology Bone Marrow Transplantation Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133 Milan, Italy
    Blood 102:1927-9. 2003
    ..We believe that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival...
  75. ncbi request reprint Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease
    Giuseppe Visani
    Haematologica 88:ELT15. 2003
  76. ncbi request reprint Cryptic translocation of PML/RARA on 17q. A rare event in acute promyelocytic leukemia
    Alfonso Zaccaria
    Hematology Unit, Santa Maria delle Croci Hospital, Viale Randi 5, 48100, Ravenna, Italy
    Cancer Genet Cytogenet 138:169-73. 2002
    ..This case adds further information on alternative ways of rearrangement of the PML/RARA genes, possibly correlated with all-trans retinoic acid resistance...
  77. ncbi request reprint A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
    Michele Baccarani
    L and A Seràgnoli Institute of Hematology and Medical Oncology, S Orsola Hospital, University of Bologna, Italy
    Blood 99:1527-35. 2002
    ....
  78. ncbi request reprint Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission
    Michele Cavo
    J Clin Oncol 24:e4-5. 2006
  79. ncbi request reprint Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95
    Russell L Basser
    CSL Ltd, 45 Poplar Rd, Parkville, VIC 3052, Australia
    J Clin Oncol 24:370-8. 2006
    ....
  80. ncbi request reprint Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway
    Roberta Bortul
    Dipartimento di Morfologia Umana Normale, Universita di Trieste, Trieste, Italy
    Br J Haematol 129:677-86. 2005
    ..Overall, our results indicate that deguelin might be used in the future for increasing sensitivity to therapeutic treatments of leukaemia cells with an active PI3K/Akt signalling network...
  81. ncbi request reprint NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia
    Michela Palmisano
    Haematologica 92:1268-9. 2007
    ..They are associated with a wide spectrum of morphologic subtypes of AML, normal karyotype and FLT3 mutations. The high frequency of NPM1 mutations might provide a suitable marker for monitoring residual disease of AML...
  82. ncbi request reprint Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer 110:1178-86. 2007
    ..It also has demonstrated promising efficacy in Ph+ ALL but is still being evaluated in phase 2 trials. In this article, the authors reviewed current knowledge on novel tyrosine-kinase inhibitors in adult Ph+ ALL patients...
  83. ncbi request reprint Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type
    Maria Grazia Tibiletti
    Anatomic Pathology Unit, University of Insubria, Ospedale di Circolo, Varese, Italy
    Hematol Oncol 25:184-8. 2007
    ....
  84. ncbi request reprint Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
    Franck Morschhauser
    Department of Hematology, Centre Hospitalier Universitaire, Lille, France
    Blood 110:54-8. 2007
    ..Nonhematologic adverse events were mild to moderate. (90)Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing...
  85. ncbi request reprint Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  86. ncbi request reprint Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
    Michele Malagola
    Chair of Haematology, Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Br J Haematol 136:87-95. 2007
    ..In this setting of patients, large prospective randomised studies should be planned...
  87. ncbi request reprint Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adu
    Marco Vignetti
    Department of Cellular Biotechnologies and Hematology, La Sapienza University, Via Benevento 6, 00161 Rome, Italy
    Blood 109:3676-8. 2007
    ....
  88. ncbi request reprint Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    Simona Soverini
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:7374-9. 2006
    ..ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients...
  89. ncbi request reprint Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
    Simona Soverini
    J Clin Oncol 24:e51-2. 2006
  90. ncbi request reprint cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib
    Michele Bianchini
    Departamento de Genetica, Instituto de Investigaciones Hematologicas Mariano R Castex, Academia Nacional de Medicina, Pacheco de Melo 3081, 1425, Capital Federal Buenos Aires, Argentina
    Cancer Chemother Pharmacol 59:349-60. 2007
    ..In this study, we used genomic scale gene expression profiling to monitor changes at transcriptional level in K562 cells during the treatment with AMI + STI571...
  91. ncbi request reprint Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Hematol Oncol 24:196-204. 2006
    ..We review current trends in the management of chronic myeloid leukaemia patients undergoing treatment with tyrosine kinase inhibitors...
  92. ncbi request reprint Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  93. ncbi request reprint May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?
    Leonardo Potenza
    Leuk Res 31:269-71. 2007
  94. ncbi request reprint Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..CCgR is durable in the majority of patients but relapse occurs in a subset...
  95. ncbi request reprint Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
    Silvia Buonamici
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Blood 99:443-9. 2002
    ..12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML...